Quantum Biopharma Ltd. (QNTM) Income from Non-Controlling Interests (2020 - 2026)

Quantum Biopharma (QNTM) has 7 years of Income from Non-Controlling Interests data on file, last reported at $13.8 million in Q1 2026.

• Quarterly Income from Non-Controlling Interests rose 57.37% year-over-year to $13.8 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $24.6 million (up 701.45% YoY) and the FY2025 annual result came in at -$27.0 million, down 80.73% from the prior year.
• Income from Non-Controlling Interests climbed to $13.8 million in Q1 2026 per QNTM's latest filing, from -$3.7 million in the prior quarter.
• The five-year high for Income from Non-Controlling Interests was $25.4 million in Q2 2023, with the low at -$34.8 million in Q4 2023.
• Average Income from Non-Controlling Interests over 5 years is $570286.4, with a median of $480112.5 recorded in 2023.
• Year-over-year, Income from Non-Controlling Interests sank 268.62% in 2023 and surged 391.31% in 2025.
• Quantum Biopharma's Income from Non-Controlling Interests stood at $5.9 million in 2022, then plunged by 689.46% to -$34.8 million in 2023, then surged by 84.33% to -$5.5 million in 2024, then surged by 32.13% to -$3.7 million in 2025, then jumped by 471.41% to $13.8 million in 2026.
• Business Quant data shows QNTM's Income from Non-Controlling Interests at $13.8 million in Q1 2026, -$3.7 million in Q4 2025, and $4.7 million in Q3 2025.